Related references
Note: Only part of the references are listed.Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?
Yoshikazu Kinoshita et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Sleep and Nocturnal Gastroesophageal Reflux An Update
Kaiser G. Lim et al.
CHEST (2018)
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
Tadayuki Oshima et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2018)
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
Kentaro Sugano
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
Hirotoshi Echizen
CLINICAL PHARMACOKINETICS (2016)
Gastrointestinal mucosal barrier function and diseases
Tadayuki Oshima et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015
Katsuhiko Iwakiri et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Unmet Needs in the Treatment of Gastroesophageal Reflux Disease
Ram Dickman et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2015)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease
L. K. Jha et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2015)
A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis
Akihito Nagahara et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Effects of Omeprazole on Sleep Disturbance: Randomized Multicenter Double-Blind Placebo-Controlled Trial
Masahito Aimi et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2014)
Efficacy of Twice-Daily Rabeprazole for Reflux Esophagitis Patients Refractory to Standard Once-Daily Administration of PPI: The Japan-Based TWICE Study
Yoshikazu Kinoshita et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Gastroesophageal reflux disease and sleep disturbances
Yasuhiro Fujiwara et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
Yasuyoshi Arikawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
Jun Matsukawa et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole
Fabio Pace et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2011)
A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg
A. Eggleston et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects
D. A. Peura et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Treatment patterns and symptom control in patients with GERD: US community-based survey
William D. Chey et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Gastro-esophageal reflux disease: the recent trend in Japan
Hiroto Miwa et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2008)
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment
Peter Bytzer et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases
K Andersson et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease - A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole
F Pace et al.
DIGESTIVE AND LIVER DISEASE (2005)
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: A randomized, placebo-controlled trial
DA Johnson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study
AJ Archimandritis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Development and evaluation of FSSG: frequency scale for the symptoms of GERD
M Kusano et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study
PO Katz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life
C Farup et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects
Y Doi et al.
PSYCHIATRY RESEARCH (2000)
Share Paper
